Compliance With Once Daily Glaucoma Medication
Completed
- Conditions
- Compliance
- Interventions
- Behavioral: Intervention
- First Posted Date
- 2006-06-05
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 700
- Registration Number
- NCT00333463
- Locations
- ๐บ๐ธ
Ft. Worth, Ft. Worth, Texas, United States
Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery
Phase 3
Completed
- Conditions
- Cataract
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 267
- Registration Number
- NCT00333255
- Locations
- ๐บ๐ธ
Lehmann Eye Center, Nacogdoches, Texas, United States
Anecortave Acetate Risk-Reduction Trial (AART)
Phase 3
Terminated
- Conditions
- AMD
- Interventions
- Other: Anecortave Acetate Vehicle
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2012-11-28
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 24
- Registration Number
- NCT00333216
- Locations
- ๐บ๐ธ
Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States
Nevanac 3-Month Safety Study With QID Dosing
Phase 3
Completed
- Conditions
- Cataract
- Interventions
- Other: Nepafenac ophthalmic suspension vehicle
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2012-03-05
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 149
- Registration Number
- NCT00332774
- Locations
- ๐บ๐ธ
Contact Alcon for Trial Locations, Fort Worth, Texas, United States
Safety and Efficacy of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus
Phase 3
Completed
- Conditions
- Cataract
- Interventions
- Drug: Next Generation Ophthalmic Irrigating Solution (NGOIS)
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2012-03-05
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 369
- Registration Number
- NCT00333268
- Locations
- ๐บ๐ธ
United States, Fort Worth, Texas, United States
Next Generation Ophthalmic Irrigating Solution Posterior Segment Study
Phase 3
Completed
- Conditions
- Eye Diseases
- Interventions
- Drug: Next Generation Ophthalmic Irrigating Solution (NGOIS)Other: BSS Plus
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2012-03-05
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 369
- Registration Number
- NCT00333203
- Locations
- ๐บ๐ธ
United States, Fort Worth, Texas, United States
Anecortave Acetate Risk Reduction Trial (AART)
Phase 3
Terminated
- Conditions
- AMD
- Interventions
- Other: Anecortave Acetate Vehicle
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2012-11-28
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 36
- Registration Number
- NCT00332657
- Locations
- ๐ฎ๐ณ
India, Bangalore, India
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Ocular HypertensionGlaucoma
- Interventions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 319
- Registration Number
- NCT00333125
AL-15469A for the Treatment of Bacterial Conjunctivitis
Phase 3
Completed
- Conditions
- Bacterial Conjunctivitis
- Interventions
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 695
- Registration Number
- NCT00332293
- Locations
- ๐บ๐ธ
Contact Alcon for Trial Locations, Fort Worth, Texas, United States
Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis
Phase 3
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 287
- Registration Number
- NCT00331500
ยฉ Copyright 2025. All Rights Reserved by MedPath